CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 29, 2013		Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (16,148)		$ (5,333)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	6,219		4,876
Share-based compensation expense	2,776		2,295
Deferred income taxes	(794)		(348)
Other accrued liabilities	394		99
Changes in current assets and liabilities, excluding effects from acquisitions:
Accounts receivable	(2,144)		(267)
Inventories	4,290		9,288
Other current assets	1,181		593
Accounts payable	2,229		(3,440)
Deferred profit	4,716		1,338
Income taxes payable, including excess stock option exercise benefit	861		747
Accrued compensation, warranty and other liabilities	(2,156)		(4,002)
Net cash provided by operating activities	1,424		5,846
Cash flows from investing activities, excluding effects from acquisitions:
Payment for purchase of Ismeca, net of cash received	(53,463)
Purchases of short-term investments			(35,312)
Sales and maturities of short-term investments	632		39,623
Purchases of property, plant and equipment	(1,253)		(1,289)
Other assets	(162)		(99)
Net cash provided by (used in) investing activities	(54,246)		2,923
Cash flows from financing activities:
Cash dividends	(1,478)		(2,920)
Issuance of stock, net of repurchases	691		934
Net cash used in financing activities	(787)		(1,986)
Effect of exchange rate changes on cash and cash equivalents	(1,759)		(852)
Net increase (decrease) in cash and cash equivalents	(55,368)		5,931
Cash and cash equivalents at beginning of period	102,808	[1]	53,262
Cash and cash equivalents at end of period	47,440		59,193
Supplemental disclosure of cash flow information:
Cash paid (refunded) for income taxes	(1,321)		234
Inventory capitalized as property, plant and equipment	572		415
Dividends declared but not yet paid	$ 1,494		$ 1,468

[1] Derived from December 29, 2012 audited financial statements